Summary
35 / 100 · Bulios Score
What speaks for it
- It has raised its dividend 12 years in a row.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 2 of the 9 points of the Piotroski financial health test.
- Revenue grew by only 2.0% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.0% a year over 5 years. Over the last 3 years it grew by 2.0% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $116.7M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 33.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 4.97%
- Raised in a row
- 12 years
You receive $1.45 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 3
- Sell 1
Today's price within the analysts' price targets
The average target of $45 is 56% above today's price. 43% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Other revenue 100%
By region
- Americas HY 83%
- EMEA HY 17%
Other revenue brings in 100% of revenue.
Segments in detail